Leukocyte disorder

This early-stage trial is testing an investigational therapy called B019, which uses a patient's own immune cells engineered to recognize and attack leukemia cells. The study focuses on people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard…

This Phase III trial is testing whether a single infusion of AZD0120, a CAR-T therapy that targets two proteins on myeloma cells, can keep the cancer at bay better than continuous standard treatment. It enrolls adults newly diagnosed with multiple myeloma who are not eligible for…

This trial is testing whether combining anti-CD19 CAR-T cell therapy with the drug lenalidomide can safely and effectively treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or not responded to prior treatments. Participants…

This trial is testing an experimental therapy called CD22 CAR T cells in adults with certain types of B cell lymphomas that have come back or not responded to previous treatments. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack…

This trial tests a new type of cell therapy called KCAT19 for people aged 16 to 65 with advanced B-cell blood cancers that have relapsed or not responded to at least two prior treatments. The therapy uses immune cells from a donor's cord blood, which are modified to recognize and…

This trial is testing whether a treatment plan tailored to each child's genetic risk can improve outcomes for relapsed acute lymphoblastic leukemia. Children and young adults up to age 22 whose leukemia has returned in the bone marrow receive a combination of chemotherapy drugs, …

This nationwide trial is testing whether adjusting chemotherapy intensity based on the amount of leukemia cells remaining after initial treatment (called minimal residual disease, or MRD) can improve outcomes for children and teens with high-risk acute lymphoblastic leukemia (ALL…

This trial tests whether using advanced genetic testing (NGS) to measure leftover cancer cells after initial treatment can help doctors tailor chemotherapy for children with standard-risk acute lymphoblastic leukemia. Around 116 children aged 1 to 10 will receive a standard chemo…

This large trial is testing whether adding the targeted drugs blinatumomab or venetoclax to standard chemotherapy can improve survival and reduce side effects in children with intermediate- or high-risk B-cell acute lymphoblastic leukemia (ALL). The study compares different sched…

This early-phase trial tests a new approach called PICX Injection, a CAR-T cell therapy that is prepared inside the patient's body rather than in a lab. It is for people with multiple myeloma that has returned or not responded to at least two prior treatments. The study will eval…

This phase I trial is testing different doses of chemotherapy given before a patient's own genetically modified immune cells (CAR T-cells) are infused to treat diffuse large B-cell lymphoma that has returned or not responded to prior treatment. The goal is to find the safest and …

This phase 3 trial is testing whether a new drug, nemtabrutinib, combined with venetoclax works better than the current standard of venetoclax plus rituximab for people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 735 p…

This phase 2 study tests an oral drug called nemtabrutinib in about 490 people with blood cancers like chronic lymphocytic leukemia, non-Hodgkin lymphoma, and Waldenstrom's macroglobulinemia. The goal is to see if the drug can shrink tumors and control the cancer, while also chec…

This study tests whether fecal microbiota transplantation (FMT) can reduce gut-related side effects from antibiotics in 40 adults with B-cell lymphoma who are receiving standard CAR-T cell therapy. Participants will receive FMT alongside their cancer treatment to see if it improv…

This phase 2 trial tests whether adding the drug nemtabrutinib to a CAR T-cell therapy called brexu-cel can help people with mantle cell lymphoma that has come back or not responded to treatment. Nemtabrutinib blocks a protein that helps cancer cells grow, while brexu-cel uses a …

This study tests whether adjusting cancer drug doses for people with the Duffy null blood trait can reduce treatment delays and dangerous fevers. About 90 participants with multiple myeloma or triple-negative breast cancer will receive standard chemotherapy with modified dosing g…

This phase 2 trial tests whether the drug nivolumab can slow or stop the growth of Epstein-Barr virus (EBV)-positive lymphoproliferative disorders and non-Hodgkin lymphomas. About 40 people aged 12 and older whose cancers have not responded to standard therapy will receive nivolu…

This study tests whether a newer drug called pirtobrutinib works better than the current standard drug ibrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 737 adults who need treatment for their cancer will be randomly assigned to receive o…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This phase 3 trial will compare two drug combinations for people newly diagnosed with multiple myeloma who are not eligible for or refuse a stem cell transplant. About 500 participants will receive either belantamab mafodotin or daratumumab, both combined with standard drugs (bor…

This study tests a new treatment called AZD0120 for people with multiple myeloma that has come back or stopped responding to at least three prior therapies. AZD0120 is a personalized cell therapy that reprograms a patient's own immune cells to attack two targets on myeloma cells …

This early-phase trial is testing a combination of two drugs—teclistamab and iberdomide—in people with multiple myeloma that has come back or stopped responding to treatment. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab. About 26…

This study tests an oral drug called KT-621 in 264 adults with moderate to severe eosinophilic asthma that is not well controlled by current treatments. Participants will take either KT-621 or a placebo daily for several weeks. Researchers will measure changes in lung function an…

This early-stage study tests a new treatment called UB-VV111 given with rapamycin for people with certain types of blood cancer (large B-cell lymphoma or chronic lymphocytic leukemia) that have come back or stopped responding to other treatments. The main goal is to check the saf…

This study tests whether a non-invasive brain stimulation technique called rTMS, given before cognitive-behavioral therapy, can help adults with cocaine use disorder quit. Thirty participants will receive either real or sham rTMS daily for 3 weeks, followed by 12 weeks of weekly …

This study tests a drug called tovorafenib (DAY101) in children and young adults (ages 6 months to 22 years) with Langerhans cell histiocytosis that has returned or not responded to treatment. The drug works by blocking enzymes that help cancer cells grow. Researchers will check …

This early-stage study tests a new drug, PF-07994525, in about 120 adults with advanced multiple myeloma that has come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. The study has two parts:…

This early-stage study is testing whether combining two drugs—teclistamab and mezigdomide—is safe and effective for people with multiple myeloma that has come back or stopped responding to other treatments. About 18 participants will receive the drugs in a specific sequence. The …

This early study tests baricitinib, a drug already approved for other immune conditions, in 20 people with Job syndrome who also have lupus-like disease or eczema. Participants take the pill daily for 6 months. The main goal is to see if it is safe and tolerable, while also check…

This study tests whether giving a personalized dose of the chemotherapy drug fludarabine before CAR T-cell therapy can improve outcomes for children and young adults with relapsed or hard-to-treat B-cell acute lymphoblastic leukemia. About 130 participants will be randomly assign…

This early-phase trial tests a personalized treatment for people with blood cancers like leukemia. Doctors take a patient's own T cells, modify them in the lab to recognize unique cancer mutations, and infuse them back after a short course of chemotherapy. The goal is to see if t…

This study tests whether adding the experimental drug zilovertamab vedotin to standard chemotherapy helps people with diffuse large B-cell lymphoma that has come back or not responded to treatment. About 290 adults will be randomly assigned to receive either the new combination o…

This early-stage trial tests an investigational drug called ABBV-438 in about 127 adults with multiple myeloma that has come back or stopped responding to treatment. The study has two parts: first, finding a safe dose, then testing that dose in more people. The main goal is to ch…

This early-phase study tests a new drug called RO7851624 in 160 people with relapsed/refractory multiple myeloma who have tried several standard treatments. The main goal is to check the drug's safety and how the body processes it. Researchers will also look for signs that the dr…

This study tests an experimental immunotherapy called MK-1045 in 200 people with two types of non-Hodgkin lymphoma: follicular lymphoma (slow-growing) and diffuse large B-cell lymphoma (fast-growing). Participants have already tried at least two other treatments without success. …

This study tests a new drug called elranatamab, alone or with another drug (daratumumab), against a standard three-drug combo for people with multiple myeloma that came back or didn't respond after at least one prior treatment. About 944 participants will be randomly assigned to …

This study compares a new immunotherapy, MK-1045, to the standard drug blinatumomab in people whose B-cell acute lymphoblastic leukemia has returned or stopped responding to treatment. About 340 adults with CD19-positive leukemia will receive one of the two treatments. The goal i…

This study tests whether adding the targeted drug zilovertamab vedotin to standard chemotherapy (R-CHP) helps people with untreated diffuse large B-cell lymphoma live longer without their cancer growing or spreading, compared to the current standard treatment (R-CHOP). About 1,04…

This early-phase trial tests the safety and best dose of the drug triapine when given together with radiation therapy for people whose glioblastoma or astrocytoma has come back. Triapine works by blocking enzymes that cancer cells need to grow, while radiation kills cancer cells …

This phase 3 trial tests an experimental drug, odronextamab, combined with lenalidomide in people with follicular or marginal zone lymphoma that has returned or not responded to treatment. The study first checks safety and dosing, then compares the new combo against the standard …

This study tests a new drug combination (glofitamab plus gemcitabine and oxaliplatin) in about 100 people with aggressive B-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see if a better steroid plan can reduce a serious side effect called …

This study tests a drug called inotuzumab ozogamicin (Besponsa) against standard chemotherapy for children aged 1 to 17 with high-risk B-cell acute lymphoblastic leukemia that has returned after initial treatment. The goal is to see if the targeted drug can clear more cancer cell…

This study tests the drug acalabrutinib in people with chronic lymphocytic leukemia (CLL) who also have moderate to severe heart failure. Researchers want to see if acalabrutinib causes fewer heart-related side effects compared to other standard treatments. About 60 adults will t…

This study tests a new drug called elranatamab for people with multiple myeloma that has returned or stopped responding to treatment. Half of the 492 participants will get elranatamab as a weekly shot; the other half will get one of several standard drug combinations. The goal is…

This study tests whether adding the experimental drug cevostamab to standard medications (pomalidomide and dexamethasone) works better than current treatments for multiple myeloma. About 380 adults whose cancer came back after 1 to 3 prior therapies will take part. The goal is to…

This large phase 2/3 trial is testing whether a new immunotherapy drug called MK-1045, when combined with the targeted therapy rituximab, can treat follicular lymphoma better than the current standard of rituximab plus chemotherapy. About 960 people with previously untreated foll…

This study tests whether adding belantamab mafodotin to lenalidomide after a stem cell transplant can turn residual myeloma cells undetectable in patients with newly diagnosed multiple myeloma. About 94 adults who have already had a transplant will receive the combination therapy…

This phase 2 study tests the drug epcoritamab in 30 people with relapsed or refractory large B-cell lymphoma who are not eligible for a stem cell transplant. Epcoritamab is a bispecific antibody that helps the immune system target and kill cancer cells. The main goal is to see ho…

This study tests whether a new drug called SCTB35, combined with standard chemotherapy, works better than the current standard treatment (rituximab plus chemo) for people whose diffuse large B-cell lymphoma has come back or stopped responding to prior therapy. About 101 adults ag…

This study tests a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in adults with B-cell lymphoma that has come back or not responded to prior treatment. The main goal is to check the safety of this drug mix. Up to 155 p…

This phase 3 trial tests whether mosunetuzumab works better than rituximab for people with a slow-growing type of lymphoma that has not spread much. Both drugs are lab-made antibodies that help the immune system attack cancer cells. About 600 adults with low tumor burden follicul…

This early-stage trial tests a new gene-editing approach for X-linked chronic granulomatous disease (X-CGD), a rare immune disorder. Researchers will collect stem cells from 10 adult male participants, use base editing to correct the genetic mutation, and return the cells after m…

This phase 3 trial compares starting treatment with venetoclax and obinutuzumab right away versus waiting until symptoms appear in people with newly diagnosed, high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. About 247 participants will be randomly assigned t…

This early-stage study tests an experimental drug called EXS73565 in about 50 adults with certain blood cancers (like lymphoma or leukemia) that returned or didn't respond to standard treatments. The main goal is to check safety and find the right dose, while also seeing if the d…

This study compares a new combination of teclistamab and pomalidomide against the standard treatment (carfilzomib, pomalidomide, and dexamethasone) for multiple myeloma that has come back after improvement. About 162 adults with relapsed or refractory myeloma will take part. The …

This Phase 2 trial is testing an investigational drug called surovatamig (AZD0486) in adults with relapsed or refractory B-cell non-Hodgkin lymphoma, including follicular lymphoma and large B-cell lymphoma. Participants must have tried at least two prior treatments. The study aim…

This study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…

This early-phase trial tests whether adding an experimental drug called SX-682 to a standard three-drug regimen is safe for people with multiple myeloma that has relapsed or become resistant. SX-682 works by freeing up immune cells to better kill cancer cells. The study will enro…

This study tests if the drug vorinostat is safe and can help people with moderate-to-severe Crohn's disease by reducing gut inflammation. Participants who respond well may then receive a maintenance treatment with ustekinumab for up to two years. The goal is to control symptoms a…

This Phase 3 trial tests whether a new drug called SCTB35, combined with lenalidomide, works better than the standard rituximab-plus-lenalidomide combo for people with follicular lymphoma that has returned or not responded to treatment. About 93 adults aged 18-80 will take part. …

This phase 2 trial is testing whether adding the drug acalabrutinib to standard chemotherapy and rituximab can improve cure rates for people with untreated diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma. About 132 adults with aggressive B-cell lymphom…

This phase 2 trial is testing whether adding tafasitamab to the standard combination of lenalidomide and rituximab can improve complete responses in people with untreated follicular lymphoma or marginal zone lymphoma. Participants receive the three-drug regimen for about a year, …

This Phase 2 trial is testing whether a CAR T-cell therapy called obecabtagene autoleucel (obe-cel) can help control newly diagnosed, high-risk B-cell acute lymphoblastic leukemia (ALL) after initial treatment. The study will enroll 30 adults with high-risk features who are in fi…

This early-phase trial is testing a new combination of two drugs—cemsidomide (a pill) and elranatamab (a shot)—in about 60 people whose multiple myeloma has come back after prior treatments. The main goal is to see if the combination is safe and to find the best dose. Researchers…

This phase 2 trial is testing a combination of two immune-based therapies—axicabtagene ciloleucel (a CAR T-cell therapy) and glofitamab (a bispecific antibody)—in 40 people with large B cell lymphoma that has relapsed or not responded to first treatment. The goal is to see if the…

This study tests a new drug called AZD0486, alone or with other cancer drugs, in people with B-cell blood cancers like certain lymphomas and leukemias. The goal is to see if it is safe and helps shrink or control the cancer. About 408 adults will take part in this early-phase tri…

This study tests whether a medicine called Panzyga can prevent major infections in people with autoimmune or rheumatic conditions who have low antibody levels after receiving B-cell depletion therapy. About 360 adults will receive either Panzyga or a placebo, and researchers will…

This phase 2 trial tests the drug mosunetuzumab in 30 people with chronic lymphocytic leukemia (CLL) who still have detectable cancer cells after at least six months of standard therapy. The goal is to see if the drug can clear those remaining cells and improve outcomes. Particip…

This study tests whether adding a targeted drug (nemtabrutinib) to a personalized cell therapy (lisocabtagene maraleucel) can help people with chronic lymphocytic leukemia or small lymphocytic lymphoma that has returned or stopped responding to treatment. About 20 adults will rec…

This study tests a breathing machine strategy that adjusts pressure based on lung measurements to protect the right side of the heart in 180 adults with moderate to severe lung failure from pneumonia. The goal is to see if this method reduces heart strain and complications compar…

This early-phase trial tests whether combining three drugs—ruxolitinib, cladribine, and venetoclax—can control T-cell prolymphocytic leukemia (T-PLL) that has returned or not responded to prior treatment. The study will enroll 36 adults and primarily monitor safety and side effec…

This early-phase study tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) for teens and young adults aged 12 to 30 whose T-cell acute lymphoblastic leukemia or lymphoma has returned or not responded to prior treatment. The main goal is to c…

This study tests whether a combination of two drugs (elranatamab and lenalidomide) can replace high-dose chemotherapy and stem cell transplant for people newly diagnosed with multiple myeloma. About 824 adults under 70 will be randomly assigned to either standard treatment or the…

This early-phase trial tests a drug called teclistamab in 30 adults with plasmablastic lymphoma that has returned or not responded to prior treatment. Teclistamab is a bispecific antibody designed to attach to both cancer cells and immune T-cells, helping the immune system attack…

This early-stage trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has returned or stopped responding to treatment. SIM0500 is a tri-specific antibody designed to help the immune system attack cancer cells. The study will first find the safest dose, t…

This study tests whether adding two oral medications (sonrotoclax and zanubrutinib) to standard CAR-T cell therapy can improve treatment results for people with mantle cell lymphoma that has come back or not responded to prior treatment. About 40 adults who are already eligible f…

This study tests a combination of three drugs (zanubrutinib, obinutuzumab, and sonrotoclax) in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if the treatment can make the cancer undetectable in the bloo…

This phase 2 trial tests a drug called mosunetuzumab, given as a shot under the skin, for people with a slow-growing type of lymphoma that hasn't been treated yet. The drug works by helping the body's immune cells find and kill cancer cells. About 30 adults will receive up to 8 c…

This study tests a drug called cosibelimab in 80 people with advanced skin cancer who also have a kidney transplant or a blood cancer. The drug works by helping the immune system attack cancer cells. Researchers will check if the tumors shrink and monitor for side effects.

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This study tests whether tirzepatide, a drug used for diabetes and weight loss, can help people with moderate to severe opioid use disorder stay in treatment and use fewer opioids when added to their regular buprenorphine medication. About 310 adults who recently started buprenor…

This study tests a CAR T-cell therapy called obe-cel in adults with B-cell acute lymphoblastic leukemia (ALL) whose cancer is in complete remission with no detectable cancer cells. The goal is to see if obe-cel can prevent the cancer from coming back. About 40 participants will r…

This study tests whether the drug elranatamab can be given safely in an outpatient clinic instead of the hospital for people with multiple myeloma that has come back or stopped responding to treatment. About 46 adults will receive the drug along with a single preventive dose of a…

This study tests a new drug, rocbrutinib, against another drug, pirtobrutinib, in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned or stopped responding to treatment. All participants have already tried a type of BTK inh…

This early-phase trial is testing a new type of immunotherapy for people with T-cell leukemia or lymphoma that has returned. The treatment involves taking a patient's own immune cells (or cells from a past stem cell donor), adding a special receptor that targets a protein called …

This phase 3 trial tests whether a new CAR T-cell therapy, KITE-753, works better than the current standard, axicabtagene ciloleucel (axi-cel), for adults with large B-cell lymphoma that returned or didn't respond to first treatment. About 550 participants will receive one infusi…

This phase 3 trial tests an experimental drug called odronextamab for people with previously untreated follicular lymphoma, a slow-growing blood cancer. The study compares odronextamab alone or with standard chemotherapy to see if it leads to better remission rates. About 822 par…

This phase II trial at Mayo Clinic is testing whether adding dasatinib and quercetin to standard CAR-T therapy can improve outcomes for people with multiple myeloma that has returned or not responded to prior treatments. The study will enroll 44 adults who have already tried at l…

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This early-stage trial tests a combination of four drugs—lenalidomide, nivolumab, rituximab, and methotrexate—in people with primary CNS lymphoma, a rare cancer of the brain or spinal cord. The goal is to find the safest dose and see if adding lenalidomide and nivolumab to standa…

This early-phase trial is testing whether adding a patient's own blood stem cells to standard CAR T-cell therapy is safe and doable for people with relapsed or refractory blood cancers like lymphoma, leukemia, and myeloma. Twenty participants will receive their own stem cells 10 …

This study tests whether a new drug called teclistamab, given after standard treatment and a stem cell transplant, can help people with a rare and aggressive blood cancer called plasma cell leukemia live longer. About 74 participants will receive either standard follow-up therapy…

This study tests whether a new drug, sonrotoclax, combined with an antibody therapy works better than the current standard treatment for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma that has come back or stopped responding to prior therapy. About 630 par…

This early-phase study tests a new kind of CAR T-cell therapy for people with multiple myeloma that has come back or not responded to at least three prior treatments. The cells are 'armored' to resist a protein (TGF-beta) that normally blocks their attack. Up to 30 adults will re…

This study tests a CAR T-cell drug called brexucabtagene autoleucel in 40 adults with B-cell acute lymphocytic leukemia that has come back or is hard to treat. Participants first receive standard chemotherapy drugs to reduce cancer, then get the CAR T-cells. The goal is to see if…

This Phase 3 trial compares a modified version of the standard DHAP chemotherapy regimen against the original in adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The modified regimen spreads out the cisplatin and cytarabine doses over several days, aiming…

This study tests whether adding dasatinib or venetoclax to standard chemotherapy can help more children with T-cell acute lymphoblastic leukemia or lymphoma achieve a deep remission. About 100 children and young adults aged 1 to 18 will receive one of these targeted drugs alongsi…

This study is testing a powerful chemotherapy regimen originally designed for children, combined with the targeted drug venetoclax and immunotherapy, in adults aged 14 to 60 with a certain type of acute lymphoblastic leukemia (ALL). The goal is to see if this approach can achieve…

This study tests if the drug elranatamab, given before and after a stem cell transplant, can better control high-risk multiple myeloma. About 40 adults with newly diagnosed, high-risk disease will receive the drug to reduce cancer cells before transplant and then as maintenance t…

This early-phase study tests a new approach for people with certain blood cancers (like lymphoma) that have returned or not responded to standard therapy. Participants receive their own immune cells that have been modified to attack cancer cells, along with specially edited stem …

This phase II trial is testing a combination of six chemotherapy drugs (clofarabine, etoposide, cyclophosphamide, liposomal vincristine, dexamethasone, and bortezomib) in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, or related cancers that have come back or…

This early-phase trial tests whether a combination of two drugs (loncastuximab tesirine and rituximab) given after precise radiation to the brain is safe and effective for central nervous system lymphoma. The study enrolls 12 adults whose lymphoma has returned or who cannot recei…

This study tests new ways to give the drug sonrotoclax to adults with chronic lymphocytic leukemia or mantle cell lymphoma. The goal is to find a dosing schedule that lowers the risk of tumor lysis syndrome, a serious side effect. About 258 participants will be enrolled to check …

This phase 2 trial tests the drug mosunetuzumab, alone or with zanubrutinib, in 152 adults with newly diagnosed follicular lymphoma who need treatment. The goal is to see how many patients achieve complete remission. Participants receive the drug as injections over several months…

This study is for people with multiple myeloma that has come back or stopped responding to other treatments. The trial has two parts: first, finding the best dose of a drug called belumosudil mesylate, and second, testing that dose alone or with dexamethasone to see if it can con…

This Phase 3 trial is testing whether the drug surovatamig can help people with a specific type of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) stay in remission longer after their first round of treatment. About 420 participants will either receive suro…

This trial tests a new approach for people with multiple myeloma that has come back or not responded to treatment. Doctors take immune cells from donated cord blood, genetically engineer them to better recognize and attack myeloma cells, and give them back to the patient along wi…

This phase 3 trial compares an experimental drug, linvoseltamab, to an existing drug, daratumumab, in 270 people with smoldering multiple myeloma at high risk of developing active multiple myeloma. The goal is to see if linvoseltamab can delay the disease longer. Participants wil…

This trial tests a new drug called SHR-3079 in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least one prior standard treatment. The main goals are to check the drug's safety, find the best dose, and get an early look at whether it can shrink tumors…

This Phase 3 trial tests whether giving immune globulin (IGI) regularly can prevent serious infections in adults with multiple myeloma who are receiving a bispecific antibody therapy. About 183 participants will be randomly assigned to get IGI right away for 12 months or only aft…

This study tests a new drug called sonrotoclax, alone or with other medicines, in people with a type of multiple myeloma that has come back or stopped responding to treatment. The trial includes 246 participants and aims to find the safest and most effective dose. Researchers wil…

This study tests an experimental drug called AZD5492 in people with B-cell cancers (like lymphoma or leukemia) that have come back or not responded to at least two prior treatments. The drug works by helping the body's T cells attack cancer cells. The trial will check safety, sid…

This phase 2 trial tests a bispecific antibody called CM336 as maintenance therapy after stem cell transplant in 20 adults with newly diagnosed multiple myeloma who still have minimal residual disease. The goal is to see if it can clear remaining cancer cells and delay relapse.

This study tests whether adding two targeted drugs, blinatumomab and venetoclax, to standard chemotherapy can improve outcomes for infants with a type of leukemia called acute lymphoblastic leukemia (ALL). About 153 infants will participate. The goal is to see if these combinatio…

This Phase 3 trial is testing an experimental oral drug called BGB-16673 against standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has already been treated with two types of targeted therapy (BTK and BCL2 inhib…

This study tests a drug called emapalumab to see if it can safely help people whose blood cell counts stay dangerously low after CAR T-cell therapy for certain lymphomas. About 32 adults who have already received standard CAR T-cell therapy will take part. The goal is to find out…

This study is tracking how well the drug zanubrutinib works and its safety in people with Waldenström macroglobulinemia, a rare blood cancer. Researchers are especially interested in patients with specific genetic mutations and those from racial and ethnic minority groups. The st…

This phase II trial is testing a combination of three drugs—zanubrutinib, rituximab, and methotrexate—given through the vein and directly into the eye, for people newly diagnosed with primary intraocular lymphoma, a rare cancer of the eye. The goal is to see if this regimen can i…

This study tests whether a stem cell transplant from a healthy donor can help people with severe primary immunodeficiencies. Participants aged 4 to 75 receive chemotherapy before the transplant to prepare their body. The goal is to see if the procedure is safe and can improve imm…

This study combines a stem cell transplant with a special immune cell therapy (C-CAR088) to treat people with ultra high-risk multiple myeloma, a blood cancer that is hard to treat. The 20 participants will receive their own stem cells after high-dose chemotherapy, followed by a …

This study tests a new treatment for people with blood cancers like leukemia, lymphoma, and multiple myeloma that have returned or not responded to treatment. Participants receive chemotherapy followed by specially engineered natural killer (NK) cells from donated cord blood. The…

This phase II trial is testing a combination of five drugs (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide, called ViPOR) in people with certain aggressive B-cell lymphomas that have come back or not responded to treatment. The study aims to see how many patien…

This phase 2 trial is testing a new CAR T-cell therapy called WZTL-002 for people with large B-cell lymphoma that has come back or not responded to standard treatment. The therapy uses a patient's own immune cells, modified to target and kill cancer cells. The study will measure …

This trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…

This phase 3 trial is testing a new oral drug, nemtabrutinib, against two standard targeted therapies (ibrutinib or acalabrutinib) in 1,200 people with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if nemtabrutinib works at least as well…

This study tests whether a new drug, zilovertamab vedotin, combined with standard chemotherapy (R-CHP) works better than another approved drug combo for people with a specific type of fast-growing blood cancer called GCB diffuse large B-cell lymphoma. About 594 adults who have no…

This phase 2 trial tests a one-time infusion of WU-CART-007, a CAR-T cell therapy made from healthy donor cells, in 125 people with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or not responded to treatment. The goal is to see if it can wipe ou…

This study compares a new drug, BGB-16673, to an existing one, pirtobrutinib, in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has come back or stopped responding to prior treatment. About 500 adults will be randomly assigned to one of the tw…

This study tests a combination of two drugs, acalabrutinib and rituximab, in elderly or frail patients with untreated diffuse large B-cell lymphoma who cannot receive standard chemotherapy. About 80 participants will receive the drugs orally and by injection. The main goal is to …

This study tests whether the antiviral drug remdesivir can help treat RSV (a common respiratory virus) in people whose immune systems are weakened by certain cancer treatments or autoimmune therapies. About 60 adults with confirmed RSV will receive remdesivir intravenously. The m…

This study tests a personalized approach for people with newly diagnosed multiple myeloma who have had a stem cell transplant. After transplant, participants receive the drug elranatamab as maintenance therapy, with the dose and duration guided by a sensitive blood test (MRD test…

This study tests a temporary device that stimulates the diaphragm (the main breathing muscle) in ICU patients on breathing machines. The goal is to see if it helps patients breathe more on their own and recover from lung injury. About 30 adults with severe breathing failure will …

This study looks at whether older adults with mantle cell lymphoma (MCL) who achieve remission can safely stop taking zanubrutinib and restart it only if the cancer returns, instead of taking it every day forever. About 421 people will be randomly assigned to either continuous or…

This early-stage study tests an experimental drug called cevostamab in about 20 Chinese adults whose multiple myeloma has returned or stopped responding to standard treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shrink tum…

This phase 2 trial tests a combination of two drugs, acalabrutinib and venetoclax, in 80 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned after initial treatment. Participants must have responded well to their first ther…

This phase 3 trial is testing whether a new combination of two oral drugs, sonrotoclax and zanubrutinib, works better than the current standard combination (venetoclax plus acalabrutinib) for people with untreated chronic lymphocytic leukemia (CLL). About 500 adults who have not …

This early-phase trial tests the safety of a new drug called karonudib in up to 9 adults with blood cancers like leukemia who have no standard treatment options left. The study aims to find a safe dose and look for any signs that the drug works. It is too early to know if karonud…

This study is testing a new experimental drug called LY4584180 in adults with certain types of blood cancer (like lymphoma) that have not improved after at least two prior treatments. The main goals are to check the drug's safety, how the body processes it, and whether it can shr…

This trial is testing whether combining a short course of focused radiation with three drugs—GM-CSF, pomalidomide, and glofitamab—can effectively treat newly diagnosed primary central nervous system diffuse large B-cell lymphoma (PCNSL), a rare and aggressive cancer of the brain …

This study is checking the long-term safety of the drug pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already been treated with other drugs. About 150 adults who completed a previous pirtobrutinib study can join. They…

This study tests a new treatment called AZD0120, which uses a patient's own immune cells engineered to attack two targets (BCMA and CD19) on myeloma cells. It is for people whose multiple myeloma has returned or stopped responding to prior treatments. The study compares AZD0120 t…

This early-stage trial tests a single-dose gene therapy called VNX-101 for people with certain blood cancers (like leukemia or lymphoma) that have returned or not responded to standard treatment. The therapy delivers instructions to the body to make a protein that helps immune ce…

This study tests a new oral drug, BGB-16673, designed to destroy a protein called BTK that helps certain blood cancers grow. The trial includes about 645 people with various B-cell cancers (like lymphoma and leukemia) that have come back or not responded to prior treatments. The …

This study is observing how well the drug glofitamab works and how safe it is for Chinese adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have already tried one prior treatment. Researchers will track 300 participants receiving glofitamab as part of t…

This study tests a new drug, cemsidomide, combined with dexamethasone in people with multiple myeloma that has returned or not responded to at least three prior treatments. About 100 adults will receive the drug combo to see if it shrinks tumors and how safe it is. The goal is to…

This Phase 3 study tests whether the drug mavorixafor can reduce serious infections and increase neutrophil levels in people with chronic neutropenia—a condition where the body doesn't make enough infection-fighting white blood cells. About 176 participants will receive either ma…

This early-stage trial tests an experimental drug called INCA036873 in about 280 adults with advanced solid tumors or certain blood cancers that have worsened after standard treatments. The main goal is to check safety and find the right dose. Participants receive the drug throug…

This early-phase study tests a new treatment for adults with certain types of blood cancer (like lymphoma) that have come back or not responded to standard therapies. The treatment combines a targeted drug (pirtobrutinib) with specially engineered immune cells (CAR T-cells) desig…

This phase 3 trial tests an experimental drug called odronextamab, given together with standard chemotherapy (CHOP), for people with diffuse large B-cell lymphoma who have not been treated before or whose cancer has come back. The study compares this new combination to the curren…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This early-phase study tests a new experimental drug, REGN17372, combined with another drug called linvoseltamab in people with relapsed or refractory multiple myeloma (cancer that has returned or stopped responding to treatment). The main goals are to check safety, find the best…

This early-stage trial is testing two drugs, mosunetuzumab and venetoclax, in people with chronic lymphocytic leukemia (CLL) that has come back or stopped responding to treatment. Mosunetuzumab is given as a shot under the skin, and venetoclax is a daily pill. The study will chec…

This phase 2 trial is testing whether paxalisib (GDC-0084), an oral drug taken daily, can shrink or control tumors in people with recurrent or refractory primary central nervous system lymphoma (PCNSL) — a rare type of non-Hodgkin lymphoma that starts in the brain or spinal cord.…

This early-stage trial is testing whether combining two drugs, cevostamab and elranatamab, is safe and tolerable for people with multiple myeloma that has returned or not responded to prior treatments. About 120 participants will receive the drugs, and researchers will monitor si…

This Phase 3 study tests whether the experimental drug glofitamab works better than standard treatments (rituximab plus bendamustine or lenalidomide plus rituximab) for people with mantle cell lymphoma that has returned or not responded to prior therapy. About 182 participants wi…

This phase 2 trial is testing a combination of blinatumomab (an immune-boosting drug) with dasatinib or imatinib (targeted pills) and standard chemotherapy for people with a specific type of leukemia called Philadelphia chromosome-positive or Philadelphia chromosome-like B-ALL. T…

This study tests a new experimental drug, REGN7945, combined with another experimental drug, linvoseltamab, in people with multiple myeloma that has returned or not responded to at least three prior treatments. The goal is to see if the combination is safe and can shrink tumors b…

This study is testing several new drug combinations for people with multiple myeloma, a type of blood cancer. The trial is open to 200 participants who have already had some treatment. The goal is to see if these combinations are safe and help control the disease. Because multipl…

This phase 3 trial is testing whether the oral targeted drug tirabrutinib works better than a standard combination of rituximab and temozolomide for people with relapsed or refractory primary central nervous system lymphoma (PCNSL). About 132 participants will be randomly assigne…

This study tests a drug called glofitamab, which helps the immune system find and kill cancer cells, in children and young adults (ages 6 months to under 30) whose B-cell lymphoma has come back or not responded to treatment. Some participants receive glofitamab alone, while other…

This phase III trial is testing whether adding inotuzumab ozogamicin—a drug that targets cancer cells—to standard chemotherapy can improve outcomes for young adults (ages 18-39) newly diagnosed with B-cell acute lymphoblastic leukemia. About 310 participants will be enrolled. The…

This Phase 3 trial compares a fixed-duration combination of zanubrutinib and sonrotoclax against continuous zanubrutinib alone in older patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The study will enroll 466 participants to see if the combo i…

This study tests whether adding the drug iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for multiple myeloma that has relapsed or become resistant. About 88 participants will receive either the new combo or the standard combo…

This trial is testing whether taking tirabrutinib daily can help people with primary central nervous system lymphoma (PCNSL) stay in remission longer after their initial chemotherapy has worked. Participants who have achieved complete remission will be randomly assigned to receiv…

This early-phase trial tests whether combining two drugs—pacritinib and a BTK inhibitor—is safe and effective for people with mantle cell lymphoma that has come back or stopped responding to treatment. Ten adults will receive the combination and be monitored for side effects and …

This study is testing whether a personalized cell therapy called MB-CART19.1 can be manufactured right at the hospital for children and adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The therapy uses the patient's own i…

This Phase III trial is testing whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of brain tumor (IDH-mutated grade 3 astrocytoma). About 408 participants will receive either vorasidenib or a pla…

This phase II trial is testing a combination of two targeted drugs, inotuzumab ozogamicin and blinatumomab, with or without ponatinib, for adults with a type of leukemia called B-ALL. The study includes newly diagnosed older adults and those whose cancer has returned or not respo…

This phase 3 trial tests a new CAR T-cell therapy called rondecabtagene autoleucel (ronde-cel) that targets two proteins (CD19 and CD20) on lymphoma cells. It is compared to standard CD19-targeting CAR T-cell therapy in 400 patients with relapsed or refractory large B-cell lympho…

This study tests an experimental drug called elenestinib (BLU-263) in people with indolent systemic mastocytosis, a rare condition where too many mast cells cause symptoms like flushing, itching, and stomach issues. About 534 participants will receive either the drug or a placebo…

This study tests an experimental drug called NX-5948 in adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to prior treatments, including BTK and BCL-2 inhibitors. The main goal is to see if the drug can shrink o…

This study tests an experimental inhaled drug called PUL-042 in 100 people with blood cancers or who have had a stem cell transplant and have a viral lung infection. Participants receive either the drug or a placebo three times over six days. The goal is to see if PUL-042 can red…

This study tests a new drug called acalabrutinib combined with standard chemotherapy (R-CHOP) in people with untreated mantle cell lymphoma who cannot have a stem cell transplant. The goal is to see how well the combination shrinks tumors and how safe it is. Participants will con…

This study tests whether combining two drugs, teclistamab and daratumumab, can help people newly diagnosed with both multiple myeloma and light chain amyloidosis. About 30 adults will receive the treatment for up to 24 cycles. The goal is to see if the combo improves survival wit…

This study tests a new drug called etentamig against standard treatments for adults with multiple myeloma that has returned or stopped responding. About 380 participants will receive either etentamig or a standard therapy chosen by their doctor. The goal is to see if etentamig ca…

This phase II trial is testing whether combining two drugs—glofitamab and chidamide—can help people with diffuse large B-cell lymphoma that has come back or not responded to earlier treatment. The study will enroll about 22 adults and measure how many achieve a complete response …

This phase III trial is investigating whether adding an experimental drug called BCD-248 to daratumumab can improve outcomes for people with multiple myeloma that has returned or become resistant to treatment. The study will compare this new combination against the current standa…

This study tests whether giving a single dose of tocilizumab before the cancer drug ramantamig can prevent or reduce cytokine release syndrome (CRS), a serious flu-like reaction. About 230 adults with relapsed or refractory multiple myeloma will participate. Half will get tociliz…

This study tests two experimental drugs (rocbrutinib and lacutoclax) taken together to treat several types of blood cancers, including lymphoma and leukemia. The goal is to see if the combination is safe and can shrink or control the cancer. About 92 adults who have already tried…

This phase 2 trial tests lacutoclax, a daily pill that blocks a protein helping cancer cells survive, in 75 adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Participants take the drug until their disease worsens or side effects become…

This early-phase trial is testing a new drug, SHR-5421, in about 97 people with multiple myeloma that has come back or stopped responding to treatment. The main goal is to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…

This early-stage study tests a new drug called MTX325 in healthy volunteers and people with mild to moderate Parkinson's disease. The main goals are to check safety, how the body processes the drug, and whether it reaches the brain. If successful, MTX325 might one day slow the pr…

This study tests whether giving tocilizumab before the first dose of linvoseltamab can lower the risk of cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma. The 30 participants have already tried at least four prior treatments. Researchers will…

This phase 3 trial is testing whether a combination of two targeted oral drugs—lisaftoclax and acalabrutinib—can work better than standard chemoimmunotherapy for people newly diagnosed with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). About 344 particip…

This study tests a new drug called ARC-02, given together with rituximab, in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least two prior treatments. The main goals are to check the safety of ARC-02 and find the best dose, while also looking at whe…

This trial investigates whether long-acting injectable antiretroviral drugs can control HIV better than standard oral pills in adults with AIDS-related lymphoma who are also receiving chemotherapy. Participants will receive one of three HIV treatment strategies—oral pills alone, …

This study tests two different drugs—dexrazoxane and liposomal doxorubicin—to see which is safer and more effective at preventing heart failure in people with a type of lymphoma called DLBCL. All 60 participants will receive standard chemotherapy (R-CHOP or pola-R-CHP), and the g…

This trial tests whether a new drug called albipagrastim alfa can prevent severe neutropenia (dangerously low white blood cell counts) in children with sarcoma who are receiving chemotherapy. The drug is designed to stimulate the body's production of infection-fighting neutrophil…

This early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…

This trial tests whether a low dose of the antifungal drug liposomal amphotericin B can prevent invasive fungal infections in children aged 3 to 17 who have prolonged neutropenia (very low white blood cell counts) after cancer treatment or stem cell transplant. The drug is given …

This trial tests an experimental drug called CM-336 in people with high-risk smoldering multiple myeloma, a condition that often leads to active cancer. The drug is a bispecific antibody designed to guide immune cells to destroy myeloma cells. Researchers want to see if it can ma…

This early-stage trial is testing an experimental drug called JNJ-95804306 in people with blood cancers like leukemia that have come back or not responded to standard treatments. The study has two parts: first, finding a safe dose, and then checking if the drug shrinks tumors whe…

This phase II trial is testing whether a combination of three targeted drugs—orelabrutinib, obinutuzumab, and a short course of venetoclax—can effectively treat people newly diagnosed with mantle cell lymphoma (MCL). The study will enroll about 39 participants who have not receiv…

This early study tests a new treatment called KSVCBD for people with a type of blood cancer called B-cell non-Hodgkin's lymphoma that has come back or not responded to other treatments. KSVCBD is a special therapy that works inside the body to help immune cells attack cancer cell…

This phase 2 trial tests a combination of three drugs—zanubrutinib, rituximab, and venetoclax—in people with previously untreated follicular lymphoma. The goal is to see if this mix can improve the rate of complete remission (disappearance of cancer). Participants receive all thr…

This study tests whether injecting sodium thiosulfate directly into abnormal calcium deposits can shrink them and reduce pain. It includes people with three rare conditions: systemic sclerosis, dermatomyositis, and a genetic disorder called iPPSD2. Participants receive up to 11 i…

This study tests an experimental drug, HDP-101, in people with multiple myeloma or related plasma cell disorders. The goal is to see if the drug is safe and can shrink tumors. Participants have already tried other treatments, including stem cell transplant or are not eligible for…

This phase 2 trial tests whether a combination of two drugs—talquetamab and lenalidomide—can help prevent multiple myeloma from returning after a stem cell transplant. The study enrolls 20 adults with symptomatic multiple myeloma who have already undergone a transplant. Participa…

This trial investigates whether combining two FDA-approved drugs, duvelisib and venetoclax, can safely and effectively treat peripheral T-cell lymphoma that has returned or stopped responding to prior therapies. The study enrolls adults who have tried at least two previous treatm…

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This phase II trial compares the anti-cancer activity of teclistamab, an immunotherapy, against the standard combination of lenalidomide and dexamethasone in people with high-risk smoldering multiple myeloma. Smoldering myeloma is a pre-cancerous condition that often progresses t…

This phase 3 trial is for people newly diagnosed with multiple myeloma who are not healthy enough for a stem cell transplant. After six months of standard treatment with daratumumab, lenalidomide, and dexamethasone, participants are assigned to different immunotherapy combination…

This early-phase study tests a new approach for patients with certain lymphomas (Hodgkin, NK/T-cell, and others) that have returned or not responded to treatment. The therapy uses immune cells from healthy donors that are specially trained in the lab to attack cancer cells carryi…

This trial investigates a combination of two drugs—tafasitamab, an antibody given by IV, and lenalidomide, an oral medication—for people with relapsed central nervous system (CNS) lymphoma. The study includes up to 35 participants and is the first to test this antibody in CNS lym…

This early-phase study tests the safety and tolerability of a new drug called HRS-1635 in 180 adults with B-cell blood cancers that have come back or not responded to treatment. Researchers will find the best dose and watch for side effects. The goal is to control the disease, no…

This phase 2 trial tests a personalized cell therapy called zamtocabtagene autoleucel (MB-CART2019.1) for people with B cell lymphomas that have come back or not responded to standard treatments. Participants receive their own immune cells that have been genetically modified to r…

This trial investigates a personalized cell therapy called CAR-T for children and young adults (ages 5–50) with B-cell acute lymphoblastic leukemia that has relapsed or not responded to standard treatment. The therapy involves collecting a patient's own immune cells, engineering …

This phase 3 trial tests whether adding an experimental drug called SG301 to two standard medications (pomalidomide and dexamethasone) can help people with multiple myeloma that has come back or stopped responding to treatment. About 360 adults aged 18–75 with measurable disease …

This trial investigates a personalized cell therapy called CAR-T, which reprograms a patient's own immune cells to recognize and attack a protein (BCMA) on multiple myeloma cells. The study enrolls 10 adults whose cancer has returned or become resistant after at least three prior…

This phase 2 trial tests whether infliximab, a drug that blocks inflammation, can prevent cytokine release syndrome (CRS) in people with relapsed or refractory multiple myeloma receiving teclistamab or talquetamab. CRS is a common and sometimes serious side effect of these treatm…

This study is looking at how well a combination of two drugs, ibrutinib and venetoclax, works for people with chronic lymphocytic leukemia (CLL) when used in everyday medical practice. Researchers will follow 60 patients who are already scheduled to receive this treatment to see …

This study tests a stem cell transplant using a reduced-intensity conditioning regimen (lower doses of chemotherapy and radiation) followed by a donor stem cell infusion. The goal is to treat various blood cancers and blood disorders while lowering the risk of graft-versus-host d…

This phase 2 trial tests a drug called pirtobrutinib in people aged 75 and older with untreated chronic lymphocytic leukemia (CLL). Pirtobrutinib is a next-generation BTK inhibitor designed to block cancer growth signals, potentially working even when other similar drugs stop bei…

This phase 2 trial tests whether adding the targeted drug orelabrutinib to standard chemotherapy, with or without a stem cell transplant, can improve outcomes for people newly diagnosed with an aggressive type of non-Hodgkin lymphoma called DLBCL. The study enrolls 30 adults aged…

This phase 2 trial is testing a combination of two drugs—CM336 (a bispecific antibody) and isatuximab (a monoclonal antibody)—in 20 people newly diagnosed with multiple myeloma who also have severe kidney impairment. The goal is to see if the treatment can improve kidney function…

This early-stage trial tests a new treatment called IBR900, made from natural killer (NK) cells, for people with a type of blood cancer called CD20-positive B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The study has two parts: first, finding t…

This trial investigates CRC01, a therapy made from a patient's own immune cells that are genetically modified to recognize and attack cancer cells. It is for adults with large B-cell lymphoma or B-cell acute lymphoblastic leukemia that has returned or not responded to previous tr…

This study tests whether adding the drug blinatumomab along with a low dose of donor immune cells (called donor lymphocyte infusion) can help prevent relapse in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already had a stem cell transplant. The trea…

This phase II trial tests whether combining brentuximab vedotin (a targeted antibody that delivers a toxin to cancer cells) with bendamustine (a chemotherapy drug) can shrink tumors in people with follicular lymphoma that has come back or not responded to prior treatment. The stu…

This phase 3 trial investigates whether adding the targeted drug acalabrutinib to a reduced-dose chemotherapy regimen (R-miniCHOP) helps older adults with untreated diffuse large B-cell lymphoma live longer without their cancer progressing. Participants are randomly assigned to r…

This phase 1 trial tests a new type of immunotherapy for people with recurrent or progressive high-grade gliomas, including glioblastoma. The treatment uses the patient's own T cells, which are genetically modified in the lab to target a protein called IL13Rα2 found on tumor cell…

This phase 2 trial tests whether a combination of iberdomide (a pill) and daratumumab (an injection) can eliminate leftover cancer cells in multiple myeloma patients who still have minimal residual disease after a stem cell transplant. About 60 participants will receive up to 26 …

This phase 2 trial tests two oral drugs, zanubrutinib and sonrotoclax, in 24 people with untreated high-risk CLL/SLL. The goal is to see if a time-limited treatment guided by minimal residual disease (MRD) can achieve deep remission. Participants take the drugs for up to 27 cycle…

This study tests a new type of immunotherapy called CAR-T cells that are designed to recognize and attack cancer cells carrying a protein called CD7. It includes people with several blood cancers, such as T-cell acute lymphoblastic leukemia and acute myeloid leukemia. The goal is…

This early-phase trial tests whether giving siltuximab before epcoritamab can prevent cytokine release syndrome (CRS), a common and sometimes severe side effect. About 20 adults with non-Hodgkin lymphoma will receive siltuximab one hour before their first epcoritamab dose. Resear…

This Phase 3 trial tests three different drug combinations for people with newly diagnosed multiple myeloma who are eligible for a stem cell transplant. The goal is to see which combination leads to the deepest remission (measured by minimal residual disease negativity) after 18 …

This trial tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD70, found on certain B cell cancers. The treatment involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing …

This study tests a new type of immunotherapy called CD22/CD19 dual-target CAR-T cells in people with high-risk B-cell acute lymphoblastic leukemia (B-ALL) who have already achieved their first remission after standard treatment. The goal is to see if this therapy can safely and e…

This study tests a new type of immunotherapy called CAR T cells that are designed to recognize several different targets on multiple myeloma cancer cells. The treatment involves taking a patient's own immune cells, modifying them in a lab to better attack the cancer, and infusing…

This phase 2 trial is testing two targeted drugs, zanubrutinib and obinutuzumab, in people with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The goal is to see if starting obinutuzumab at different times leads to deep remission wher…

This Phase 2 trial is testing a stem cell transplant from a donor for people with various blood cancers and bone marrow disorders. The transplant uses strong chemotherapy or radiation to wipe out the diseased marrow, then replaces it with healthy donor cells. A new combination of…

This study tests a new approach using a mix of gene-modified immune cells (CAR-T cells) that target multiple proteins found on B cell lymphoma cells. The goal is to see if this combination is safe and can shrink tumors in patients whose cancer has not responded to standard treatm…

This trial investigates a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia (B-ALL) whose cancer has stopped responding to anti-CD19 treatment. The therapy uses a patient's own immune cells, modified to target several other markers on leukemia cel…

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD22, on the surface of B cell cancer cells. The treatment involves infusing these engineered immune cells into patients whose B cell malignancies have returned or not r…

This study tests a new type of immunotherapy called bi-specific CAR-T cells that target two proteins, CD19 and CD79b, found on B cell cancers. The therapy involves collecting a patient's own immune cells, modifying them to recognize and attack cancer cells, and infusing them back…

This study tests a combination of four drugs—isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd)—in people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. The goal is to see how well the regimen controls the disease and what si…

This early-stage trial tests a combination therapy for B-cell acute lymphoblastic leukemia (B-ALL). It uses specially engineered immune cells (CAR-T cells and CTLs) followed by a dendritic cell vaccine to target multiple cancer markers. The goal is to achieve a very deep remissio…

This study tests a new treatment called 4SCAR-CD44v6 T cells for people with cancers that have a specific protein called CD44v6. The therapy uses a patient's own immune cells, modified to better recognize and attack cancer cells. The trial will enroll 100 participants to check sa…

This early-phase trial tests a two-part immune therapy for people with T-cell acute lymphoblastic leukemia (T-ALL). First, patients receive specially engineered T cells (CAR-T) that target multiple markers on leukemia cells. Then, they get a booster with cytotoxic T cells and a d…

This early-phase trial tests a new 'universal' CAR T cell therapy (4SCAR19U) for people with B cell cancers that have come back or not responded to treatment. The therapy uses donor-derived immune cells engineered to target CD19 on cancer cells. The study aims to check safety and…

This early-phase trial tests whether adding two drugs—loncastuximab and roflumilast—to the standard R-CHOP chemotherapy regimen can safely treat people with untreated, high-risk diffuse large B-cell lymphoma (DLBCL). The study enrolls about 10 adults with this aggressive lymphoma…

This phase 1 trial tests an experimental drug, DXC006, in people with advanced solid tumors (like small cell lung cancer and neuroblastoma) or blood cancers (like multiple myeloma) who have not responded to standard treatments. DXC006 is an antibody-drug conjugate designed to del…

This phase 2 trial tests a combination of three drugs—carfilzomib, cyclophosphamide, and dexamethasone—in 20 people newly diagnosed with POEMS syndrome, a rare disorder affecting nerves and blood. The goal is to see if the regimen can reduce abnormal proteins and improve symptoms…

This early-phase trial tests a new injection called IASO207 for people with relapsed or refractory B-cell blood cancers. Unlike current CAR-T therapies that require removing and engineering cells in a lab, IASO207 is designed to create cancer-fighting T cells directly inside the …

This early study tests a new treatment called RN1201 for people newly diagnosed with multiple myeloma, a type of blood cancer. RN1201 uses specially engineered immune cells from a healthy donor to target and kill cancer cells. Participants receive a single infusion of these cells…

This study tests a new immune cell therapy (dual-target CD22/CD19 CAR-T cells) as a consolidation treatment for people with standard-risk B-cell acute lymphoblastic leukemia (B-ALL) who are in remission. The goal is to see if it is safe and can help prevent the cancer from coming…

This phase 1 trial is testing a new way to dose the chemotherapy drug melphalan for people with multiple myeloma who are getting a stem cell transplant. Instead of a standard dose, the amount is personalized based on each patient's blood levels after a test dose. The goal is to f…

This study tests a program called PASCA that helps doctors detect and manage complications like high blood pressure, kidney failure, chronic pain, and fatigue in multiple myeloma patients after a stem cell transplant. About 204 adults aged 18 to 70 will be randomly assigned to ei…

This phase III trial is testing three different drug combinations for people newly diagnosed with multiple myeloma who are considered frail or intermediate-fit and are not getting a stem cell transplant. The study compares three-drug induction regimens followed by either double o…

This study tests a new combination of drugs for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The experimental drug is a liposomal form of mitoxantrone, given with standard chemotherapy and rituximab. The trial has two parts: first, finding the safest dose, t…

This trial is for people newly diagnosed with a high-risk form of multiple myeloma, a blood cancer. It tests several new drug combinations to see which works best at killing cancer cells and keeping the disease from coming back. About 300 participants will receive different treat…

This early-phase trial is testing a new cell therapy called TBI-2001 for people with certain blood cancers (B-cell lymphoma, CLL, SLL) that have come back or not responded to at least two prior treatments. The therapy uses a patient's own immune cells, modified to recognize and a…

This study tests whether a combination of two drugs, zanubrutinib and tislelizumab, along with standard care, can help people with large B-cell lymphoma whose cancer got worse after CAR-T cell therapy. About 76 adults will take part. The goal is to see if the treatment can shrink…

This early-stage trial tests a new treatment called IC19/1563 for people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recogn…

This study tests a drug called balstilimab in 20 adults with certain lymphomas (classical Hodgkin lymphoma or primary mediastinal B-cell lymphoma) that have returned or not responded to standard treatments. Participants receive the drug every 3 weeks to see if it shrinks tumors a…

This early-phase trial is testing a CAR-T cell therapy made using an automated process for people with relapsed or refractory large B-cell lymphoma. The study will enroll 12 adults whose cancer has not responded to or returned after first-line treatment. Researchers will measure …

This study compares a new combination of two drugs (mosunetuzumab and lenalidomide) against standard chemotherapy for people with untreated follicular lymphoma. About 790 participants will be randomly assigned to one of the two treatments. The goal is to see if the new combo keep…

This early-phase study tests whether giving sirolimus before standard bispecific antibody therapy can improve T-cell function and treatment response in people with multiple myeloma. About 10 participants will receive sirolimus first, then the antibody treatment. The main goals ar…

This early-phase study tests a new drug called [90Y]Y-PentixaTher for people with central nervous system (CNS) lymphoma that has come back or not responded to standard treatments. The drug delivers radiation directly to cancer cells. About 15 participants will receive one intrave…

This early-phase trial tests whether high-dose vitamin C, combined with a lower dose of the chemotherapy drug melphalan and a stem cell transplant, is safe and effective for people with relapsed multiple myeloma. The study enrolls 18 adults who have already tried at least three p…

This study tests whether adding a drug called golcadomide after standard CAR T-cell therapy can prevent aggressive large B-cell lymphoma from returning in patients at high risk of relapse. About 65 adults will receive golcadomide for 24 weeks starting 5 days after their CAR T-cel…

This early-stage trial is testing a new treatment called KSVCBD for people with multiple myeloma that has come back or not responded to at least three prior treatments. KSVCBD is a type of CAR-T cell therapy given directly into the body to target two proteins (CD19 and BCMA) on m…

This early-phase trial tests a new approach to treat central nervous system (CNS) lymphoma by injecting specially engineered immune cells (CAR T cells) directly into the fluid surrounding the brain. The study involves 20 participants and aims to find the safest dose while monitor…

This early study tests adding daratumumab, an antibody that targets a protein on cancer cells, to standard chemotherapy for people with newly diagnosed plasmablastic lymphoma, a rare and fast-growing cancer. The trial includes up to 15 participants, with or without HIV. The main …

This early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …

This study compares two pneumococcal vaccination strategies in 160 adults with lymphoma who have had chemotherapy. One group gets two vaccines (Prevenar 13 followed by Pneumovax 23), while the other gets a single newer vaccine (Prevenar 20). Researchers will measure immune respon…

This phase 2 trial tests whether adding leflunomide to the standard drugs pomalidomide and dexamethasone can better control multiple myeloma that has come back or is resistant to treatment. About 29 adults with relapsed or refractory myeloma will receive the three-drug combinatio…

This early-phase study tests a personalized neoantigen vaccine (NeoVax) in 15 people with untreated chronic lymphocytic leukemia (CLL) who have a specific genetic marker (IGHV unmutated). The vaccine is designed to train the immune system to attack each person's unique cancer cel…

This study tests a new combination of drugs for people with a specific type of untreated diffuse large B-cell lymphoma (DLBCL). The goal is to see if the treatment can keep the cancer from coming back for at least two years. About 35 participants will receive six cycles of the dr…

This early-stage trial tests a new type of immunotherapy called CAR T-cells, which are made from a patient's own immune cells and engineered to recognize and attack a protein called KMA on myeloma cells. The study will enroll 12 adults with relapsed or refractory multiple myeloma…

This study tests whether a blood test (ctDNA) can help doctors choose the right treatment for people with a type of lymphoma that happens after an organ transplant (PTLD). About 30 participants will be split into low-risk and high-risk groups. Low-risk patients will get only the …

This study tests whether giving the drug epcoritamab before and after CAR-T cell therapy can help people with relapsed or refractory large B-cell lymphoma. About 31 adults will receive epcoritamab injections, then CAR-T cells, and possibly more epcoritamab if lymphoma remains. Th…

This early-stage trial is testing a new type of immunotherapy for children and young adults with a high-risk or relapsed form of acute lymphoblastic leukemia. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack leukemia cells tha…

This study tests a combination of five drugs (R-PMDT) in 33 people newly diagnosed with primary central nervous system lymphoma, a rare brain cancer. The goal is to see how many patients' tumors shrink or disappear after six cycles of treatment. Researchers will also track how lo…

This study tests whether specially engineered immune cells (CAR-NK cells) can safely treat people with advanced thymus cancers that have not responded to other treatments. Participants will receive cells that target one of three proteins found on their tumor. The goal is to find …

This Phase 2 trial tests whether adding zanubrutinib to standard chemotherapy (R-CHOP) can better treat newly diagnosed diffuse large B-cell lymphoma that shows p53 protein expression. About 41 adults aged 18–75 will receive the combination. The main goal is to see how many patie…

This study tests a combination of two drugs, belantamab mafodotin and venetoclax, with or without dexamethasone, in people whose multiple myeloma has come back and is hard to treat. The cancer must have a specific genetic change called t(11;14). The goal is to find the safest dos…

This early-phase trial is testing a new type of CAR-T cell therapy, called CD19-CAR.p40-T, in 10 adults with B-cell lymphoma, acute lymphoblastic leukemia, or acute myeloid leukemia that has come back or not responded to treatment. Participants receive chemotherapy followed by an…

This early-stage study is testing a new gene therapy that reprograms a patient's own immune cells to attack two targets (CD19 and CD20) on cancer cells. The trial will enroll 30 adults with B-cell cancers that have come back or not responded to treatment. The main goals are to ch…

This phase 2 trial tests whether adding a short course of radiation to the drug glofitamab can help people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who have large tumors. About 40 adults in China will receive glofitamab plus radiation. The main goal is to…

This study tests a new type of immunotherapy called CD19/CD22 CAR-T cells as an early consolidation treatment for people with follicular lymphoma who still have some disease after standard chemotherapy. About 20 participants will receive a single infusion of their own modified im…

This pilot study tests a stem cell transplant method that removes specific immune cells (alpha/beta T cells and B cells) from the donor cells before transplant. The goal is to reduce the risk of graft-versus-host disease, a serious complication, while still allowing the transplan…

This early-stage trial tests whether adding the targeted drug zanubrutinib to a standard chemotherapy regimen (Pola-R-CHP plus high-dose methotrexate) is safe for people with large B-cell lymphoma that has spread to the central nervous system (brain or spinal cord). About 20 adul…

This early-stage trial tests a new treatment called DuoCAR20.19.22-D95 for adults with B-cell lymphoma or leukemia that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, which are modified in the lab to better recognize and attack…

This study compares two treatments—Shengbai Oral Liquid (a herbal remedy) and Leucogen tablets (a standard drug)—for moderate neutropenia (low white blood cells) caused by anti-tumor drugs in breast cancer patients. Sixty participants will be randomly assigned to receive one trea…

This phase 3 trial is testing whether 4 cycles of R-CHOP followed by 4 cycles of rituximab is as safe and effective as the standard 6 cycles of R-CHOP plus 2 cycles of rituximab for people with newly diagnosed, low-risk diffuse large B-cell lymphoma. The study plans to enroll 640…

This study tests a new drug called F182112 against standard treatments in 261 adults with multiple myeloma that has returned or stopped responding to prior therapies. The goal is to see if the new drug can delay cancer growth longer than usual care. Participants must have already…

This study tests whether a single injection of Telpegfilgrastim works better than daily Filgrastim shots to prevent fever and low white blood cells in children and young adults (ages 6-24) with solid tumors receiving strong chemotherapy. About 132 participants will receive either…

This study tests a new type of CAR-T cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell acute lymphoblastic leukemia or T-cell lymphoma that has come back or not responded to treatment. The trial has two phases: first, finding the safest …

This study looks at whether a simple breathing test (spirometry) can help doctors decide the right dose of immunoglobulin therapy for people with common variable immune deficiency (CVID). Researchers will enroll 22 adults with CVID who already take a stable dose of Hizentra. Half…

This study tests whether raising blood levels of a natural molecule called beta-hydroxybutyrate (BHB) — through a strict ketogenic diet or ketone drinks — is safe and can improve the effectiveness of immunotherapy (CAR-T cells or bispecific antibodies) in 45 adults with multiple …

This phase II trial compares standard chemotherapy with newer drug combinations for people whose follicular lymphoma has returned or stopped responding to treatment. About 284 participants will receive either standard therapy or one of several experimental regimens, including a b…

This Phase 2 trial tests whether fasudil, a drug already used in Japan and China for brain blood vessel spasms, can improve memory and brain function in people with early Alzheimer's disease. Two hundred participants will receive either fasudil or a placebo for 12 months, with re…

This early-stage study tests a new drug called LP-284 in about 110 adults whose lymphomas or solid tumors have returned or stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug move…

This study tests an experimental drug called AVTX-803 in people with leukocyte adhesion deficiency type II (LAD II), a rare genetic condition that weakens the immune system and leads to frequent infections. The trial will compare the drug against a period without treatment to see…

This study tests a lotion called QRX003 in people with Netherton Syndrome, a rare genetic skin condition. About 16 participants aged 4 and older will apply the lotion twice daily for 12 weeks. Researchers will check if it improves skin appearance and reduces itching.

This study is for people with blood cancers like leukemia who are getting chemotherapy or a stem cell transplant, which can cause very low white blood cell counts (neutropenia) for over a week. The goal is to see if the antibiotic eravacycline can prevent serious bacterial infect…

This phase 2 trial is testing whether a radioactive tracer called 18F-fluciclovine can detect multiple myeloma better than the standard FDG tracer during PET/CT scans. The study will enroll 60 adults with newly diagnosed or relapsed/refractory multiple myeloma. Each participant w…

This study tests whether a special PET scan using a tracer called 68Ga-Pentixafor can better detect and predict the course of blood cancers like lymphoma, multiple myeloma, and leukemia. The tracer targets a protein on cancer cells, potentially offering clearer images than standa…

This trial investigates whether a special MRI technique using hyperpolarized carbon-13 pyruvate can safely and effectively detect primary central nervous system lymphoma, a rare type of brain cancer. Participants receive an injection of the substance before an MRI scan, and resea…

This study is testing whether a blood test that looks for tumor DNA in the bloodstream (called a liquid biopsy) can help doctors manage patients with mature B-cell tumors. The goal is to see if the test can accurately predict who is cured after treatment and identify early signs …

This study is testing a new radioactive tracer called 68Ga-EV203 for PET/CT scans in people with blood cancers like multiple myeloma, lymphoma, and leukemia. The goal is to see how the tracer spreads in the body, how much radiation it gives off, and whether it can find tumors bet…

This early-phase trial is testing a new radioactive imaging agent called 64Cu-LLP2A to see if it can safely and clearly show blood cancers like multiple myeloma and lymphoma on PET/CT scans. The study includes healthy volunteers and patients with these cancers, including those wh…

This early-stage study tests a single dose of a new radioactive tracer called [68Ga]Ga-R54, which attaches to a protein (CXCR4) found on some cancer cells. Ten adults with advanced solid tumors or multiple myeloma will receive the tracer and then have a PET/CT scan to see where i…

This study tests a special PET/CT scan that uses radioactive tracers to find cancers that have a protein called CD70 on their surface. The cancers being studied include kidney cancer, lymphoma, and nasopharyngeal cancer. About 300 adults will receive an injection of the tracer an…

This study looks at whether a low dose of the antifungal drug liposomal amphotericin B can prevent serious fungal infections in adults with blood cancers or who have had stem cell transplants and have a prolonged low white blood cell count (neutropenia). The trial enrolls 30 pati…

This study tests whether a fecal microbiota transplant (FMT) can prevent graft-versus-host disease (GvHD) in 150 adults with blood cancers who receive a stem cell transplant. Patients get a single FMT enema within four weeks of transplant. The main goal is to see if FMT improves …

This phase 3 trial is testing whether adding Gamunex-C (an immune globulin) to standard care can prevent serious infections in people with chronic lymphocytic leukemia, multiple myeloma, or non-Hodgkin lymphoma. About 49 participants will receive Gamunex-C through an IV every 4 w…

This trial tests a program called ACT, which trains doctors and nurses to have compassionate, structured conversations with blood cancer patients and their families about end-of-life care. The goal is to help patients understand their prognosis and make informed decisions, potent…

This trial tests whether a dedicated 'return-to-work after cancer' consultation can help people who have been treated for blood cancers like leukemia, lymphoma, or multiple myeloma get back to their jobs. The consultation, led by an occupational health specialist with possible su…

This study tests a program that teaches family caregivers how to help their loved ones with mild to moderate dementia manage chronic pain. Researchers will work with 60 people (30 patients and their caregivers) to see if the training improves pain coping and quality of life. The …

This trial tests whether a specially designed website, called Mosaic, can help blood cancer patients who are about to undergo a stem cell transplant feel less distressed and have a better quality of life. Participants are randomly assigned to use either the Mosaic website or a st…

This study tests whether a 9-week strength training program using resistance bands and body weight exercises is practical for children aged 6-21 newly diagnosed with acute lymphoblastic leukemia or lymphoblastic lymphoma. The program combines at-home exercises with optional Zoom …

This study tests whether a tailored physical activity program can help older adults maintain thinking and memory after a stem cell transplant for blood cancers. Participants aged 60 and older will follow a progressive, light-to-moderate exercise plan with support from therapists …

This study tests whether a 12-week, app-guided exercise program is safe and practical for adults with primary antibody deficiencies—conditions where the immune system struggles to fight infections. Researchers will track how many people join and finish the program, how often they…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This study tests a personalized program combining exercise and nutrition advice to help reduce fatigue in people with indolent (slow-growing) lymphomas, such as chronic lymphocytic leukemia and follicular lymphoma. Participants receive an individualized exercise plan and dietary …

This study looks at whether a custom website can improve quality of life for people with multiple myeloma. About 108 adults with newly diagnosed or returning myeloma will use the platform to report side effects and get personalized tips. The goal is to see if this digital support…

This study tests whether carefully timed lighting can help multiple myeloma patients undergoing their first stem cell transplant. Two hundred participants will receive either bright morning light and dim evening light, or dim light all day. Researchers will measure sleep quality,…

This study tests a new drug called EI-1071 in 15 people with mild to severe Alzheimer's disease. The main goal is to see if the drug is safe and tolerable over 4 weeks. Researchers will also check if it reduces brain inflammation using special brain scans. Participants must have …

This study tests whether a very low dose of radiation (2 Gy) can relieve bone pain in people with multiple myeloma that has spread to the bones. The goal is to see if this gentler approach works as well as standard radiation but with fewer side effects and less disruption to chem…

This early trial is testing whether loratadine, better known as the allergy medicine Claritin, can reduce bone pain caused by a drug called G-CSF in people with multiple myeloma who are having their stem cells collected. The study will compare pain levels between those taking lor…

This study tests an online cognitive training program called I-CAN in 90 adults with relapsed multiple myeloma or B-cell non-Hodgkin lymphoma who are about to receive CAR-T cell therapy. The training aims to reduce the memory, attention, and thinking problems that often follow ca…

This pilot study is testing whether music therapy delivered over video calls is a practical way to help blood cancer survivors who have trouble with memory, attention, and thinking. Researchers will enroll 60 adults who have had lymphoma, leukemia, or myeloma. Participants will e…

This study tests whether a breathing therapy device (adaptive servo ventilation) can reduce insomnia severity in adults with moderate to severe chronic insomnia. About 25 participants will use the device and report changes in sleep quality and how long it takes to fall asleep ove…

This study is testing whether a 6-month, personalized exercise program can improve the quality of life for people with multiple myeloma. The program mixes in-person sessions at the hospital with at-home workouts. Researchers will compare participants who get the exercise program …

This natural history study follows up to 4,000 people with inherited bone marrow failure syndromes (IBMFS) and their families to learn why they are prone to certain cancers. Researchers will track health over time, collect genetic samples, and look for clues that separate those w…

This study looks at the tiny organisms living on our skin—like bacteria and fungi—and how they might differ in people with eczema (atopic dermatitis). Researchers will collect skin samples from healthy volunteers and patients aged 2 to 40 with moderate to severe eczema, as well a…

This study aims to understand how and why eosinophils (a type of white blood cell) become active in conditions like allergies, asthma, and parasitic infections. Researchers will observe up to 800 people aged 1 to 100 with high eosinophil levels. No experimental treatments are giv…

This study aims to understand the causes and progression of Common Variable Immunodeficiency (CVID) and related inborn errors of immunity. Researchers will observe up to 500 patients over time using blood tests, imaging, and other exams. The goal is to find better ways to diagnos…

This study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…

This study looks at how common certain antibodies and inflammatory markers are in people with chronic granulomatous disease (CGD). Researchers will measure levels of adenovirus-fighting antibodies and inflammatory cytokines in blood samples from 60 adults and children with CGD. T…

This study gathers fluid and tissue from the lungs and nose of healthy volunteers and people with a history of lung infections. Researchers will compare samples to find differences in immune function that might explain why some people are more prone to infections. Participants un…

This study aims to understand why some people are more prone to fungal infections, especially from Candida yeast. Researchers will collect blood, saliva, urine, and tissue samples from people with immune disorders, their family members, and healthy volunteers. No treatment is giv…

This study collects blood, urine, bone marrow, and tumor samples from people with hairy cell leukemia and other blood cancers, as well as from healthy volunteers. Researchers will use these samples to study the diseases and develop new treatments called immunotoxins, which use an…

This study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …

This study tests whether regular blood and bone marrow tests using advanced DNA sequencing can better monitor children with B-cell acute lymphoblastic leukemia (B-ALL) after they achieve remission with CAR T therapy. The goal is to see if these tests can identify who is truly cur…

This study collects blood stem cells and immune cells from healthy volunteers and patients with primary immune deficiencies or blood disorders. The cells are used in the lab to develop new gene and cell therapies. Up to 850 adults aged 18-70 will participate. The goal is to advan…

This study follows 950 people with idiopathic CD4+ lymphocytopenia (ICL), a rare condition where low CD4+ white blood cells raise infection risk. Researchers will track participants for up to 10 years, collecting medical history, blood samples, and infection data. The goal is to …

This study tests a decision-support tool called PRIME for adults aged 60 and older with blood cancers like leukemia or lymphoma. The tool helps patients clarify their values and shares that information with their doctors. The goal is to see if using PRIME leads to treatment decis…

This study is tracking 500 people with chronic lymphocytic leukemia (CLL) who are taking venetoclax, either alone or with other drugs, as part of their normal care in Austria, Germany, and Switzerland. Researchers want to see how well the treatment works in real-life settings and…

This study is observing up to 3,500 people with immune system problems, including rare genetic conditions like chronic granulomatous disease and severe combined immunodeficiency. Researchers will track how these diseases change over time through blood tests, imaging, and checkups…

This study follows 1,500 people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases — rare conditions where the virus drives abnormal immune cell growth. Researchers will collect medical history, treatment details, and blood samples to see how the diseases beh…

This study investigates how acetate, a substance produced when the body breaks down alcohol, is used by the brain in heavy drinkers. Researchers will use a special imaging technique to track acetate metabolism and measure stress hormone levels. The goal is to understand the link …

This study aims to find how common the KIT D816V mutation is in people with suspected clonal mast cell disease. Researchers will collect blood samples from 450 participants and test them using two sensitive methods. The results may improve understanding and diagnosis of these rar…

This study tracks genetic changes in chronic lymphocytic leukemia (CLL) cells during treatment with the drug venetoclax. Researchers aim to understand how the cancer evolves as the drug is started. 75 adults with relapsed or refractory CLL will receive venetoclax and undergo regu…

This study looks at gene changes that might cause low blood cell counts (cytopenia) in people with multiple myeloma or certain lymphomas after CAR-T therapy. About one-third of patients have low blood counts lasting more than 30 days after treatment. Researchers will test blood a…

This study from Stanford University is looking at how a 6-week math training program changes brain activity and thinking skills in children with math learning disabilities (dyscalculia). About 180 children aged 6-12 will do math problems on a tablet at home and get weekly one-on-…

This study is looking for 2,000 people who have a close family member with a blood cancer like multiple myeloma. The goal is to find early warning signs of the disease by collecting blood samples and health information over time. Participants will not receive any treatment, but t…

This study aims to collect stem cells from people with a rare condition called idiopathic CD4 lymphocytopenia (ICL) and from healthy volunteers. Participants receive two medications to move stem cells from bone marrow into the blood, where they are collected. The stem cells are t…

This observational study will follow 30 multiple myeloma patients receiving a standard CAR-T therapy called cilta-cel. Researchers will collect blood, bone marrow, and other samples to find biomarkers linked to rare toxicities like nerve damage, blood issues, and gut problems. Th…

This study provides ongoing check-ups for people who received a donor stem cell transplant at the NIH at least three years ago. Researchers will monitor for late side effects, disease return, and overall health. Participants will have yearly visits that may include blood tests, b…

This study aims to learn more about rare disorders that affect how the body processes chemicals called pyrimidines and purines. These disorders can cause problems in the brain, blood, kidneys, and immune system, ranging from mild to life-threatening. Researchers will compare test…

This study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…

This study creates a global registry for people with mitochondrial disorders—rare diseases that affect energy production in cells. By collecting health data from 6,000 participants worldwide, researchers aim to understand how these diseases progress and identify the best ways to …

This study watches people with blood cancers like CLL who take BTK inhibitors or venetoclax to see how these drugs affect heart rhythm. Researchers will use EKGs, stress tests, and heart monitors to track abnormal rhythms and sudden death risk. The goal is to better understand an…

This study gathers blood and leftover tissue samples from 200 people newly diagnosed with aggressive non-Hodgkin lymphoma, including types like diffuse large B-cell lymphoma and T-cell lymphoma. The samples are used to develop and validate blood-based tests that could monitor can…

This study is testing whether daily voice recordings can help doctors spot early signs of a brain-related side effect called ICANS in people receiving CAR T-cell therapy for non-Hodgkin lymphoma or multiple myeloma. About 20 participants will use their smartphones to record their…

This study looks for new ways to kill T-cell leukemia and lymphoma cells by disrupting their internal balance of reactive oxygen species. Researchers will test drug combinations in lab-grown cells and in samples from 120 patients with resistant disease. The goal is to find treatm…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study is a large registry that will collect medical information and biological samples from up to 10,000 adults with acute lymphoblastic leukemia (ALL) and related blood cancers. The goal is to track how patients are diagnosed, treated, and how they fare over time. By gather…

This study follows people who previously received zamtocabtagene autoleucel, a CAR-T cell therapy for certain types of lymphoma. The goal is to monitor long-term health outcomes, including any new cancers, neurological issues, or autoimmune problems. By tracking participants over…

This study looks at why some people with Common Variable Immunodeficiency (CVID) develop complications not caused by infections. Researchers will test whether a type of immune cell called peripheral helper T-cells (Tph) helps faulty B-cells produce antibodies that lead to these c…

This study watches how indolent systemic mastocytosis (ISM) affects people in everyday life. Researchers will collect information on symptoms, treatments, and quality of life from 150 adults. The goal is to better understand the disease and how it is managed, including the use of…

This study follows about 50 members of a family with a rare inherited condition called familial hypereosinophilia, where high levels of a type of white blood cell can damage the heart and nerves. Researchers will track participants over many years with yearly checkups, blood test…

This study looks at how well vaccines for flu, COVID-19, shingles, hepatitis B, and pneumonia work in people with certain blood cancers like chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas. Researchers will measure immune responses through blood samples before and af…

This early-stage study looks at how the liver handles two experimental drugs, AZD9550 and AZD6234, in people with moderate to severe liver problems compared to healthy volunteers. About 28 adults will receive a single injection of one drug. The goal is to see if liver impairment …

This study collects blood, urine, bone marrow, and tissue samples from over 1,200 adults with lymphoid cancers or precancerous conditions. The goal is to help researchers better understand cancer biology, which may lead to new methods for diagnosing or treating these diseases. No…

This study collects bone marrow and blood samples from up to 600 people with mastocytosis, a condition where too many mast cells cause symptoms like itching and bone pain. Researchers will study what makes these cells grow and survive. The goal is to learn more about the disease,…

This study is building a large database of information from thousands of people with plasma cell disorders, including multiple myeloma and related conditions. By tracking their health over many years, researchers hope to identify patterns that predict how the disease will progres…

This study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…

This study follows 400 people in Norway with multiple myeloma, plasma cell leukemia, or AL amyloidosis who are receiving newer immunotherapies like teclistamab, elranatamab, or CAR-T cell therapy outside of clinical trials. Researchers will track how well these treatments control…

This study looks at how letting cancer patients choose which genetic results they receive affects their understanding, expectations, and satisfaction. Adults with certain cancers (cholangiocarcinoma, multiple myeloma, or early-onset colon or rectal cancer) can join. Participants …

This study creates a registry for people with hairy cell leukemia (HCL), a rare form of adult leukemia. Researchers will track disease course, treatments, infections, and patient-reported outcomes over time. The goal is to identify trends, improve care, and design future clinical…

This study investigates whether the health of a patient's immune cells can predict how well they will respond to CAR-T or bispecific antibody treatments for relapsed multiple myeloma. Researchers will analyze blood samples from patients aged 65 and older before they start standar…

This study investigates how chronic lymphocytic leukemia (CLL) cells change their energy use when they are in the lymph node environment, which may help them resist standard treatments. Researchers are building a lab model using patient leukemia cells and normal lymph node cells …

This research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …

This study collects extra blood and bone marrow samples from people receiving CAR-T cell therapy for lymphoma or acute lymphoblastic leukemia. The goal is to build a biobank that researchers can use to investigate why about half of patients do not respond to this treatment. Parti…

This study follows 500 adults in the Languedoc-Roussillon region of France who have or are suspected of having a blood cancer (hematologic malignancy). Researchers will collect medical records, blood samples, and quality-of-life questionnaires to track survival at 2, 5, and 10 ye…

This study examines the medical records of 400 people diagnosed with various types of lymphoma at a French hospital between 1999 and 2018. Researchers want to see how long patients survived and whether the care they received matched what medical guidelines recommend. The goal is …

This observational study is recruiting 300 active-duty service members and military beneficiaries diagnosed with B-cell non-Hodgkin lymphoma. Researchers want to understand how exposure to toxins, genetic differences, and immune system problems are linked to this cancer. Particip…

This study explores whether advanced PET/CT scans using special tracers can predict how well patients with aggressive lymphoma will respond to treatment and their long-term outlook. Researchers will inject two types of imaging agents—FAPI and Grazytracer—to visualize the tumor's …

This observational study will look at 500 people with diffuse large B-cell lymphoma (DLBCL) in the Middle East and Africa. Researchers want to understand patient characteristics, current treatment patterns, and how easily patients can access newer therapies like CAR-T cell therap…

This early-stage study looks at how a new drug, INCB123667, behaves in the bodies of 16 adults with moderate or severe liver disease. Researchers will measure drug levels and watch for side effects. The goal is to gather safety information, not to treat the liver condition.

This study investigates whether changes in the GBA and PSAP genes are more common in people with multiple myeloma or its precursor condition, MGUS. Researchers will compare the frequency of these gene variants in 300 patients against known population databases. The goal is to bet…

This study looks at whether targeted cancer drugs called TKIs affect brain health and well-being in people with chronic leukemia. Researchers will compare 400 patients who receive TKI therapy to those who do not. The goal is to understand if these treatments cause cognitive chang…

This study follows 6,000 people with histiocytic disorders (like Langerhans cell histiocytosis) to understand long-term health problems, pain, mental health, and causes of death. Researchers compare participants to healthy controls to identify factors that lead to new health issu…

This study aims to collect DNA samples and detailed eye exam data from 1,000 people with rare inherited eye diseases like aniridia, Best disease, and albinism. Participants provide a saliva or blood sample and share their eye health records. The goal is to expand a research repos…

This study collects blood and tissue samples from 200 adults with HIV and certain cancers (like Kaposi sarcoma, lymphoma, or anal cancer) to help researchers understand how HIV and cancer are connected. Participants donate samples, which are stored for future research. There is n…

This observational study follows 350 adults with blood cancers like lymphoma or multiple myeloma who are being treated with bispecific antibodies. Researchers will track how often infections occur, how severe they are, and what factors raise infection risk. The goal is to better …

This study follows 270 young women treated for lymphoma with chemotherapy to see how their ovaries recover over 5 to 10 years. Researchers measure hormone levels and egg counts to understand long-term fertility and pregnancy rates. The goal is to help doctors give better advice o…

This study is creating a large database of information and tissue samples from 1,000 people with T-cell lymphoma. Researchers will use this data to learn more about the disease and how to improve patient outcomes. Participants provide medical information and optional blood and na…

This study is a worldwide registry that follows 5,000 adults with breast cancer, blood cancers, or those on immune checkpoint inhibitors. Researchers collect medical records, lab results, and imaging to identify who is at risk for heart problems during or after cancer treatment. …

This observational study is collecting genetic and clinical information from 520 people with multiple myeloma to better understand why the disease progresses or comes back. Researchers will analyze tumor DNA and RNA to find patterns linked to treatment response. The goal is to cr…

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study looks at a rare event where an aggressive lymphoma (DLBCL) comes back as a slow-growing (indolent) lymphoma. Researchers will review medical records of 50 adults to understand how often this happens, what treatments are used, and how well patients do. The goal is to ga…

This study looks at how the immune system of healthy adults in Cambodia reacts to viruses that can spread from animals to people. Researchers will collect blood samples from 400 people who have close contact with animals, such as those working in wet markets or living near bat ca…

This study follows 2000 people with multiple myeloma in the West-Occitanie region of France to see how they are treated in real life and how their quality of life changes over time. Researchers will collect data from medical records and ask patients to fill out questionnaires abo…

This study collects tumor samples and medical information from people with lymphoma or related blood cancers who have a family history of these diseases. Researchers want to find genetic changes that may increase the risk of developing lymphoma. Participants provide blood or tiss…